Company: DMAC
Filing Date: 2025-07-21
Form Type: 8-K
Source: 0001437749-25-023048
Chunk: 0

Company: DiaMedica Therapeutics Inc.
Filing Date: 2025-07-21
Form: 8-K
Item: Item 1.01
Chunk 0
---
Item 1.01      Entry into a Material Definitive Agreement.  

Private Placement and Securities Purchase Agreement

On July 21, 2025, DiaMedica Therapeutics Inc., a corporation existing under the laws of British Columbia, Canada (the “ Company”), entered into a securities purchase agreement (the “ Securities Purchase Agreement”) with a number of existing stockholders who are accredited investors (collectively, the “ Purchasers”), pursuant to which the Company agreed to issue 8,606,426 common shares, no par value, of the Company (collectively, the “ Shares”), in a private placement (the “ Private Placement”). The per Share purchase price is $3.50. The closing of the Private Placement is expected to occur on or about July 23, 2025, subject to the satisfaction of customary closing conditions.

The Company expects to receive gross proceeds of $30.1 million, before deducting fees and other offering expenses incurred in connection with the Private Placement. The Company expects to use the net proceeds from the Private Placement to continue its preeclampsia clinical development program for DM199 and for other working capital and general corporate purposes.

Registration Rights Agreement

Under the terms of the Securities Purchase Agreement, the Company agreed to enter into a registration rights agreement (the “ Registration Rights Agreement”) with the Purchasers pursuant to which the Company will agree to prepare and file a registration statement (the “ Resale Registration Statement”) with the United States Securities and Exchange Commission (the “ SEC”) within 10 business days of the closing of the Private Placement for purposes of registering the resale of the Shares. Under the terms of the Registration Rights Agreement, the Company will agree to use its commercially reasonable best efforts to cause this Resale Registration Statement to be declared effective by the SEC as promptly as possible after the filing thereof, but in any event no later than 30 calendar days following the closing of the Private Placement (or 75 calendar days in the event of a “full review” of the Resale Registration Statement by the SEC), and to keep such Resale Registration Statement effective at all times until the Shares are no longer considered “ Registrable Securities” under the Registration Rights Agreement. If the Company fails to meet the specified filing deadlines or keep the Resale Registration Statement effective, subject to certain permitted exceptions, the Company will be required to pay liquidated damages to the Purchasers. The Company also will agree, among other things, to indemnify the selling holders under the Resale Registration Statement from certain liabilities and to pay